Korro Bio Inc. (KRRO) Operating Sales Margin

Public company logo of Korro Bio Inc. (KRRO)

Korro Bio, Inc. (KRRO) holds a strong position in RNA editing, utilizing the OPERA platform for the safe correction of mutations. The final operating margin, with GURU.Markets data illustrated on this chart, shows that -5796.00 serves as the current parameter value. The company aims to capture the rare pathology market through temporary genome correction, offering breakthrough, reversible treatments during its active growth phase.

Korro Bio, Inc (KRRO): Operating Margin from 02/21/2024 to 11/19/2026

Korro Bio, Inc - analytical breakdowns and key metrics (KRRO)

- share price and consensus valuation forecast:
Fundamental company analysis:Korro Bio, Inc, KRRO
Core merchandise of Korro Bio Inc.

Operating margin determines the efficiency of the core business by measuring the share of profit before taxes and interest. Positive dynamics in this ratio signal cost optimization and increased model scalability to the investor. By analyzing the operating profitability trend, one can assess the asset's real risk premium. For Korro Bio, Inc. (KRRO), this indicator will become key during the transition to the commercialization of RNA editing therapy. Successful clinical trials will transform current expenditures into multi-billion dollar contracts with health insurers.

Competing companies

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|Operating Profitability uniQure Pharma|MGTX - Operating Profitability Margin|Operating Margin RGNX|Operating Profitability SLDB (Solid Biosciences)|Ocugen Corp - Operating Sales Margin|PACB: Return on Sales by Operating Profit|benitec.com - Operating Margin|DSGN - Operating Margin|RCKT: Operating Margin|FDMT (4D Molecular Therapeutics Inc) - Operating Profitability|Operating Sales Margin LXEO|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability